Belimumab (BEL), a human monoclonal antibody inhibiting B cell activating factor (BAFF) is approved worldwide for the treatment of several SLE manifestations and when added to standard-of-care it may gradually reduce proteinuria and the risk for LN [1]. This evidence concerns the gene TNFSF13B and lobular neoplasia.